Programmeofthe36thAnnualMeeting
oftheETA,
Pisa8th–12thSeptember2012
SATURDAY,8thSeptember
Pre‐conferenceevents
MainAuditorium
08.00‐14.00 ETA‐CRNandESESMeeting
AjointsessionofEuropeanThyroidAssociation‐CancerResearchNetwork
andEuropeanSocietyofEndocrineSurgeons
FermiHall
08.00‐15.30 ICCIDDWest‐CentralEuropeRegionalMeeting
CisanelloHospital,Pisa
08.15‐15.15 ThyroidUltrasoundandultrasound‐assistedprocedures
PacinottiHall
12.00‐13.00 TFIPatientForum
PacinottiHall
14.00‐15.30 ETA2012ItalianSatelliteSymposium“UpdateinEndocrinology”
MainAuditorium
16.00‐18.00 BayerHealthCareSatelliteSymposium
Impactoftargetedtherapiesonthetreatmentofdifferentiatedthyroid
cancer(DTC)
MainAuditorium
18.15‐19.00 TheEuropeanThyroidJournalLecture
Chairperson:WilmarM.Wiersinga,TheNetherlands
Editor‐in‐ChiefoftheEuropeanThyroidJournal
Theroleoftheiodothyroninedeiodinasesinthyroidphysiology
P.ReedLarsen,USA
19.30
WelcomereceptionattheLeopoldaStation
1
SUNDAY,9thSeptember
MainAuditoriumandFermiHall
08.00‐10.00OralSession1:TopicHighlights(OP1‐OP6)
Chairpersons:TheoVisser,TheNetherlands;PaoloVitti,Italy
08.00‐08.20 OP1
CLINICALANDBIOCHEMICALACTIVITYINTHEEXAMTRIAL,APHASE3STUDYOFCABOZANTINIB
(XL184)INPATIENTSWITHHEREDITARYANDNON‐HEREDITARYMEDULLARYTHYROIDCARCINOMA
(MTC)
EliseiR1,MuellerS2,SchöffskiP3,BroseM4,ShahM5,LicitraL6,JarzabB7,MedvedevV8,KreisslMC9,NiederleB10,
CohenE11,WirthL12,AliH13,ClaryD14,MangeshkarM14,BallD15,NelkinB15,ShermanS16,SchlumbergerM17
1UniversityofPisa,DepartmentofEndocrinology,Pisa,Italy,2UniversityHospitalofEssen,Essen,Germany,3UZ
Leuven,Leuven,Belgium,4UniversityofPennsylvaniaHealthSystem,Philadelphia,UnitedStates,5OhioState
UniversityMedicalCenter,Columbus,UnitedStates,6IstitutoNazionaledeiTumori,Milano,Italy,7Centrum
Onkology,Instytutim.M.Sklodowskiej‐CurieoddzialwGliwicach,Gliwicach,Poland,8MedicalRadiology
ResearchCenterofRAMS,Obnisk,RussianFederation,9UniversityHospitalofWuerzburg,Wuerzburg,
Germany,10MedicalUniversityofVienna,Vienna,Austria,11UniversityofChicagoMedicalCenter,Chicago,
UnitedStates,12MassachusettsGeneralHospital,Boston,UnitedStates,13HenryFordHealthSystem,Detroit,
UnitedStates,14Exelixis,SouthSanFrancisco,UnitedStates,15JohnHopkinsHospitalandHealthSystem,
Baltimore,UnitedStates,16MDAndersonCancerCenter,Houston,UnitedStates,17InstitutGustaveRoussy,
Paris,France
08.20.08.40 OP2
EFFICACYANDSAFETYOFTHREEDIFFERENTCUMULATIVEDOSESOFINTRAVENOUS
METHYLPREDNISOLONEFORMODERATE‐TO‐SEVEREANDACTIVEGRAVES'ORBITOPATHY(GO):A
MULTICENTER,RANDOMIZED,DOUBLE‐BLINDCLINICALSTUDYOF159PATIENTS
BartalenaL1,KrassasG2,WiersingaWM3,MarcocciC4,SalviM5,DaumerieC6,BournaudC7,StahlM8,SassiL1,
VeronesiG9,AzzoliniC10,BoboridisKG11,MouritsMP12,SoetersMR3,BaldeschiL12,NardiM13,CurròN14,BoschiA15,
BernardM16,vonArxG17,EuropeanGrouponGraves'Orbitopathy(EUGOGO)
1UniversityofInsubria,Clinical&ExperimentalMedicine,Varese,Italy,2PanagiaGeneralHospital,
Endocrinology,Diabetes&Metabolism,Thessaloniki,Greece,3AcademicMedicalCenter,Endocrinology&
Metabolism,Amsterdam,Netherlands,4UniversityofPisa,Endocrinology&Metabolism,Pisa,Italy,5University
ofMilan,MedicalSciences,Milan,Italy,6UniversitécatholiquedeLouvain,InternalMedicine,Brussels,Belgium,
7GHE‐HospicesCivilsdeLyonandLyon1University,Endocrinology&NuclearMedicine,Lyon,France,
8Kantonsspital,Endocrinology&Metabolism,Olten,Switzerland,9UniversityofInsubria,Clinical&
ExperimentalMedicine,Epidemiology&PreventiveMedicine,Varese,Italy,10UniversityofInsubria,Surgical&
MorphologicalSciences,SectionofOphthalmology,Varese,Italy,11AhepaHospital,Ophthalmology,
Thessaloniki,Greece,12AcademicMedicalCenter,Amsterdam,Netherlands,13UniversityofPisa,Neuroscience,
SectionofOphthalmology,Pisa,Italy,14OspedaleMaggiorePoliclinico,Ophthalmology,Milan,Italy,15Université
CatholiquedeLouvain,Ophthalmology,Brussels,Belgium,16GHE‐HospicesCivilsdeLyonandLyon1
University,Neuro‐OphthalmologyOutpatientClinics,Lyon,France,17InterdisziplinairesZentrumfurEndokrine
Orbitopathie,Ophthalmology,Olten,Switzerland
08.40‐09.00 OP3
DEFECTIVEVASCULARDEVELOPMENTISASSOCIATEDWITHABNORMALTHYROIDORGANOGENESISIN
ZEBRAFISH
OpitzR1,MaquetE1,AntonicaF1,CostagliolaS1
2
1IRIBHM,UniversitéLibredeBruxelles,Brussels,Belgium
09.00‐09.20 OP4
IMPACTOFTHETHYROCYTE‐SELECTIVEINACTIVATIONOFTHEMEN1GENEONTHEBASALANDTSH‐
STMULATEDGROWTHOFTHETHYROIDGLAND
Selmi‐RubyS1,DuPayratJ1,D'orazioT1,BonnavionR1,ZhangCX1,RoussetB1,Borson‐ChazotF1
1CRCLInsermU1052,UniversitéLyon1,FacultédeMédecineRTH‐Laennec,Lyon,France
09.20‐09.40 OP5
MYOCARDIALINFARCTIONINDUCESANUNEXPECTEDCARDIACMICRORNASIGNATUREOF
PLURIPOTENCY,ASSOCIATEDWITHIMPAIREDTHYROID‐HORMONESIGNALING
JanssenR1,ZuidwijkM1,MuldersJ2,MullerA1,OudejandC2,SimonidesW1
1InstituteforCardiovascularResearch/VUUniversityMedicalCenter,DepartmentofPhysiology,Amsterdam,
TheNetherlands,2VUUniversityMedicalCenter,DepartmentofClinicalChemistry,Amsterdam,The
Netherlands
09.40.10.00 OP6
PROTEOMICSDIFFERENTIATEBETWEENGRAVES'ORBITOPATHYANDDRYEYESYNDROME‐A
PROSPECTIVEANDCONTROLLEDSTUDY
MatheisN1,GrusFH2,KnychI1,BreitenfeldM1,KahalyGJ1
1GutenbergUniversityMedicalCenter,DepartmentofMedicineI,Mainz,Germany,2GutenbergUniversity
MedicalCenter,ExperimentalOphthalmology,Mainz,Germany
MainAuditoriumandFermiHall
10.00‐10.10 LissitzkyCareerAward
Chairpersons:TheoVisser,TheNetherlands;LuigiBartalena,Italy
10.10‐10.30 CoffeeBreak
PacinottiHall
10.30‐12.00 Symposium1:Geneticcausesofcongenitalhypothyroidism
Chairpersons:RobertoDiLauro,Italy;MassimoTonacchera,Italy
10.30‐11.00 Defectsinthyroiddevelopment
JulianeLeger,France
11.00‐11.30 DUOXa2
SamuelRefetoff,USA
11.30‐12.00 DEHAL
JoseMoreno,Spain
3
MainAuditoriumandFermiHall
10.30‐12.00 Symposium2:Thyroidandmentalhealth
Chairpersons:UllaFeldt‐Rasmussen,Denmark;StefanoMariotti,Italy
10.30‐11.00 Iodineanddevelopmentaloutcomes
MichaelZimmermann,Switzerland 11.00‐11.30 Hypothyroidismandmentalhealth
ColinDayan,UK
11.30‐12.00 Hyperthyroidismandmentalhealth
TorquilWatt,Denmark
PosterArea
12.00‐13.00 LunchandPosterDiscussion1(Posters1‐121)
PosterSession1:MTCBasicandtranslational
Chairperson:M.ChiaraZatelli,Italy
PosterSession2:ThyroidCancerDiagnosticsClinical1
Chairperson:JeanLouisWemeau,France
PosterSession3:ThyroidCancerPathogenesisBasic
Chairperson:MartinSchlumberger,France
PosterSession4:ThyroidCancerTherapeuticsClinical1
Chairperson:CamillaSchalin‐Jantti,Finland
PosterSession5:ClinicalThyroidAutoimmunity1
Chairperson:PatriceRodien,France
PosterSession6:ThyroidhormoneandtheCardiovascularSystem
Chairperson:FabioMonzani,Italy
PosterSession7:Graves’OrbitopathyClinical1
Chairperson:PetrosPerros,UK
PosterSession8:HypothyroidismClinical1
Chairperson:PeterTaylor,UK
PosterSession9:SubclinicalThyroidDisease
Chairperson:ValentinFadeyev,Russia
PosterSession10:GoiterandNodularDiseaseClinical1
Chairperson:RolandGärtner,Germany
PosterSession11:ImaginginThyroidology
Chairperson:MuratErdogan,Turkey
PosterSession12:CaseReports1
Chairperson:IstvanSzabolcs,Hungary
PosterSession13:ThyroidHormoneAction1
Chairperson:MariaJesusObregon,Spain
4
MainAuditorium
13.00‐14.00GenzymeSymposium
DifferentiatedThyroidCarcinoma:FromthelumptotheLongterm
FollowUp
13.00‐13.05
13.05‐13.20
13.20‐13.35
13.35‐13.50
13.50‐13.55
13.55‐14.00
Opening,Welcomeandintroduction
Chairpersons:FurioPacini,Italy;MartinSchlumberger,France
Diagnosticstrategiestoworkoutthenodulardisease
LaszloHegedus,Denmark
Ablationofthyroidremnants:whenandhow?
MarkusLuster,Germany
LongTermfollowupofthethyroidcancerpatient
RossellaElisei,Italy
Discussion
ClosingRemarks
FurioPacini,Italy,MartinSchlumberger,France
14.00‐14.45 Meet‐the‐Expert1‐4
Room90A
14.00‐14.45 MTE1:Alternativesplicingofthyroidhormonepathwaygenesincancer
AgnieszkaPiekielko‐Witkowska,Poland
FermiHall
14.00‐14.45 MTE2:Stimulatedcalcitonincut‐offsbydifferenttests
LauraFugazzola,Italy
MainAuditorium
14.00‐14.45 MTE3:Amiodarone‐inducedthyroiddysfunction
EnioMartino,Italy
PacinottiHall
14.00‐14.45 MTE4:Thethyroidandmetabolicsyndrome
GeorgBrabant,Germany
14.45‐15‐00 CoffeeBreak
15.00‐15.45 Meet‐the‐Expert5‐8
PacinottiHall
15.00‐15.45 MTE5:Deiodinaseregulationduringinflammationandinfection(Basic)
AnitaBoelen,TheNetherlands
Room90A 15.00‐15.45 MTE6:Geneticrearrangementsinthyroidcancer(Basic)
CorinneDupuy,France
MainAuditorium
15.00‐15.45 MTE7:Clinicaldebate:thishousebelievesthatallpregnantwomenshould
5
bescreenedforthyroiddysfunction
For:BrigitteVelkeniers,Belgium,Against:BijayVaidya,UK,Chairperson:John
Lazarus,UK
FermiHall
15.00‐15.45 MTE8:Hashimoto’sthyroiditisinchildren(Clinical)
MarekNiedziela,Poland
MainAuditorium
16.00‐18.00OralSession2:YoungInvestigatorSession(OP7‐OP14)
Chairpersons:JosefKöhrle,Germany;PeterLaurberg,Denmark
16.00‐16.15 OP7
HYPOXIA‐INDUCIBLEFACTOR2α(HIF‐2α)EXPRESSIONCORRELATESWITHCLINICALLYAGGRESSIVE
THYROIDTUMOURS.INVITRO,HYPOXIA‐MODULATEDTARGETSAREREGULATEDBYBOTHHIF‐1/HIF‐
2ANDPROMOTERADIO‐RESISTANCE
BurrowsN1,2,ReschJ2,BrabantG2,WilliamsK1
1UniversityofManchester,HypoxiaandTherapeuticsgroup,SchoolofPharmacy,Manchester,UnitedKingdom,
2MedClinicI‐UniversityofLuebeck,ExperimentalandClinicalEndocrinology,Luebeck,Germany
16.15‐16.30 OP8
THYROIDHORMONEANDTRα1FORMANEUROGENICSWITCHREPRESSINGSOX2INTHEADULT
NEURALSTEMCELLNICHE
RemaudS1,Lopez‐JuarezA1,HassaniZ2,MorvanG1,DemeneixB1
1MuséumNationald'HistoireNaturelle,UMRCNRS7221,EvolutiondesRégulationsEndocriniennes,
DépartementRégulations,DéveloppementetDiversitéMoléculaire,Paris,France,2King'sCollegeLondon,
CentrefortheCellularBasisofBehaviour,TheJamesBlackCentre,London,UnitedKingdom
16.30‐16.45 OP9
FACILITATIONOFMEMORYACQUISITIONANDRETENTIONINMOUSEBY3‐IODOTHYRONAMINE
MusilliC1,ManniME1,DeSienaG1,SabaA2,MarchiniM2,ZucchiR2,RaimondiL1
1UniversitàdiFirenze,Firenze,Italy,2UniversitàdiPisa,Pisa,Italy
16.45‐17.00 OP10
MIR‐218ISAMARKEROFOXIDATIVEPHOSPHORYLATIONPROCESSINONCOCYTICTHYROID
TUMOURS
CaratS1,GuillotinD2,LePennecS2,HoulgatteR1,SavagnerF2
1InsermU915,Nantes,France,2InsermU694,Angers,France
17.00‐17.15 OP11
CLINICALPHENOTYPEOFANEWTYPEOFTHYROIDHORMONERESISTANCECAUSEDBYMUTATIONOF
6
THET3RECEPTORTRα1
vanMullemA1,vanHeerebeekR1,ChrysisD2,VisserE1,MediciM1,AndrikoulaM3,TsatsoulisA3,VisserTJ1,Peeters
R1
1ErasmusMC,InternalMedicine,Rotterdam,Netherlands,2UniversityofPatras,DepartmentofPediatrics,
DivisionofEndocrinology,Patras,Greece,3UniversiyofIoannina,DepartmentofEndocrinology,Ioannina,
Greece
17.15‐17.30 OP12
TWONOVELCHIMERICTSHRECEPTORBIOASSAYSMEASURINGTHYROID‐STIMULATINGAND
BLOCKINGAUTOANTIBODIESDIFFERENTIATETHYROIDALVERSUSORBITALINVOLVEMENTIN
PEDIATRICGRAVES'DISEASE‐AMULTICENTERTRIAL
DianaT1,BossowskiA2,SawickaB2,Borysewicz‐SanczykH2,PietrewiczE2,ZioraK3,BossowskaA4,KanitzM1,Kim
J5,OlivoPD5,KahalyGJ1
1GutenbergUniversityMedicalCenter,DepartmentofMedicineI,Mainz,Germany,2MedicalUniversityin
Bialystok,DepartmentofPediatrics,Endocrinology,DiabetologywiththeCardiologyDivision,Bialystok,
Poland,3MedicalUniversityofSilesia,DepartmentofPediatricsinZabrze,Katowice,Poland,4InternalAffair
andAdministrationMinistryHospital,DepartmentofCardiology,Bialystok,Poland,5DiagnosticHybrids,Inc,R
&D,Athens,UnitedStates
17.30‐17.45 OP13
NEWSOMATICMUTATIONSANDCLONALEVOLUTIONINAGGRESSIVEPAPILLARYTHYROID
CARCINOMAREVEALEDBYWHOLE‐TRANSCRIPTOMEDEEPSEQUENCING
LePennecS1,GacquerD1,DetoursV1,MaenhautC2
1IRIBHM‐ULB,Bruxelles,Belgium,2IRIBHM‐ULB‐Welbio,Bruxelles,Belgium
17.45‐18.00 OP14
IGSF1GENEDELETIONCAUSECENTRALHYPOTHYROIDISMANDMACROORCHIDISMWITHDECREASED
OFTSHBIOACTIVITY
EscuderoA1,GorbenkoD2,BarrioR3,VallespínE4,NevadoJ4,DeGraaffL2,LapunzinaP4,Hokken‐KoelegaA2,
MorenoJC1
1InstituteforMedicalandMolecularGenetics(INGEMM).LaPazUniversityHospital,ThyroidMolecular
Laboratory,Madrid,Spain,2PediatricEndocrinology,SophiaChildren'sHospital.ErasmusUniversityMedical
Center,Rotterdam,Netherlands,3RamónyCajalUniversityHospital,PediatricEndocrinology,Madrid,Spain,
4InstituteforMedicalandMolecularGenetics(INGEMM).LaPazUniversityHospital,StructuralGenomic
Laboratory,Madrid,Spain
MainAuditorium
18.05‐18.50SpecialLectureinhonourofProf.AldoPinchera
Chairpersons:TheoVisser,TheNetherlands;LuigiBartalena,Italy
Immunopathogenesisofchronicautoimmunethyroiditisonecenturyafter
Hashimoto
AntonyP.Weetman,UK
7
MainAuditorium
19.00‐20.30MerckSeronoSymposium
ThyroidHormoneSubstitutionofHypothyroidism:searchingfortheOptimum
Moderation:GeorgeJ.Kahaly,Germany
Shortintroduction:GeorgeJ.Kahaly
Impactofhypothyroidismonthecardiovascularsystem
BernadetteBiondi,Italy
TargetingtheT4substitutioninthyroidcancer
JenniferSipos,USA
NewEuropeanguidelinesforacombinedT3/T4substitution
BirteNygaard,Denmark
20.30‐21.30 Symposiumparticipantsarecordiallyinvitedtothecocktailreception
8
MONDAY,10thSeptember
MainAuditorium
08.00‐10.00OralSession3:ClinicalThyroidology(OP15‐OP22)
Chairpersons:BirteNygaard;Denmark;ClaudioMarcocci,Italy
08.00‐08.15 OP15
MENTALVULNERABILITYISHIGHINPREVIOUSLYTREATEDHYPERANDHYPOTHYROIDISM
PerrildH1,KnudsenN1,BjergvedL1,2,CarleA3,BulowI3,VejbjergP1,LaurbergP3,OvesenL4,RasmussenL5,
JørgensenT2
1BispebjergUniversityHospital,DepartmentofEndocrinology,Copenhagen,Denmark,2ResearchCentrefor
PreventionandHealth,TheCapitalregionofDenmark,Glostrup,Denmark,3AalborgHospital,Aarhus
UniversityHospital,DepartmentofEndocrinology,Aalborg,Denmark,4SlagelseHospital,Departmentof
Gastroenterology,Slagelse,Denmark,5NationalFoodInstitute,DepartmentofNutrition,Copenhagen,Denmark
08.15‐08.30 OP16
THEASSOCIATIONBETWEENHYPERTHYROIDISMANDMORTALITYISNOTEXPLAINEDBYPRE‐
EXISTINGCO‐MORBIDITY,BUTINFLUENCEDBYGENETICCONFOUNDING.EVIDENCEFROMADANISH
NATION‐WIDEREGISTER‐BASEDSTUDYOFTWINSANDSINGLETONS
BrandtF1,AlmindD2,ChristensenK2,3,4,GreenA5,HegedüsL1,BrixTH1
1OdenseUniversityHospital,DepartmentofEndocrinologyandMetabolism,Odense,Denmark,2Universityof
SouthernDenmark,TheDanishAgingResearchCenterandTheDanishTwinRegistry,Odense,Denmark,
3OdenseUniversityHospital,DepartmentofClinicalGenetics,Odense,Denmark,4OdenseUniversityHospital,
DepartmentofClinicalBiochemistryandPharmacology,Odense,Denmark,5UniversityofSouthernDenmark,
OdensePatientdataExploratoryNetwork,InstituteofClinicalResearch,Odense,Denmark
08.30‐08.45 OP17
AGEANDGENDERSUBSTANTIALLYINFLUENCETHERELATIONSHIPBETWEENTHYROIDSTATUSAND
LIPOPROTEINPROFILE:RESULTSFROMALARGECROSS‐SECTIONALSTUDY
TogniniS1,PoliniA1,PasqualettiG1,UrsinoS1,FerdeghiniM2,MonzaniF1
1UniversityofPisa,InternalMedicine,Pisa,Italy,2UniverstyofVerona,MorphologicalandBiomedicalSciences,
Verona,Italy
08.45‐09.00 OP18
HYPOTHYROIDISMISASSOCIATEDWITHCURRENTBUTNOTWITHINCIDENTHYPERTENSION
IttermannT1,TillerD2,MeisingerC3,AggerC4,NauckM1,RettigR1,HofmanA5,JorgensenT4,LinnebergA4,
WittemanJCM5,FrancoOH5,GreiserKH2,WerdanK2,DöringA3,KluttigA2,StrickerBHC5,VölzkeH1
1UniversityofGreifswald,Greifswald,Germany,2Martin‐Luther‐UniversityHalle‐Wittenberg,Halle,Germany,
3GermanResearchCenterforEnvironmentalHealth,München,Germany,4UniversityofCopenhagen,
Copenhagen,Denmark,5ErasmusMedicalCenter,Rotterdam,TheNetherlands
9
09.00‐09.15 OP19
THEEFFECTOFHYPOTHYROIDISMONCOLOURVISION:APROSPECTIVESTUDY
CakirM1,OzturkB2,TuranE1,GonulalanG1,PolatI3,GunduzK2
1KonyaUniversityMeramSchoolofMedicine,DivisionofEndocrinologyandMetabolism,Konya,Turkey,
2KonyaUniversityMeramSchoolofMedicine,DepartmentofOphthalmology,Konya,Turkey,3KonyaUniversity
MeramSchoolofMedicine,DepartmentofInternalMedicine,Konya,Turkey
09.15‐09.30 OP20
REDUCTIONOFLEVOTHYROXINE(L‐T4)REQUIREMENTSINHYPOTHYROIDOBESEPATIENTSAFTER
BARIATRICSURGERY
MartinelliS1,PincheraA1,FierabracciP1,PiaggiP2,TamberiA1,BasoloA1,CeccariniG1,MarsiliA1,ScartabelliG1,
LandiA2,VittiP1,SantiniF1
1UniversityofPisa,SchoolofMedicine,EndocrinologyUnit,ObesityCenter,Pisa,Italy,2UniversityofPisa,
DepartmentofElectricalSystemsandAutomation,Pisa,Italy
09.30‐09.45 OP21
TAZDOESNOTRESCUETHELUNGPROMOTERACTIVITYOFANOVELNKX2‐1MUTATIONINABOY
WITHSEVERELUNGEMPHYSEMA
MoyaCM1,GarzónL2,LunaC3,SimónR4,ZaballosMA5,SantistebanP5,GallegoE2,MorenoJC1
1INGEMM‐InstituteforMedicalandMolecularGenetics.'LaPaz'UniversityHospital,ThyroidMolecular
Laboratory,Madrid,Spain,2'12deOctubre'UniversityHospital,PaediatricEndocrinology,Madrid,Spain,3'12
deOctubre'UniversityHospital,PaediatricPneumologyandAllergy,Madrid,Spain,4'12deOctubre'University
Hospital,Neuropediatric,Madrid,Spain,5BiomedicalResearchInstitute,EndocrinePhysiopathologyand
NervousSystem,Madrid,Spain
09.45‐10.00 OP22
PERIPHERALTISSUEBIOMARKERSINRESISTANCETOTHYROIDHORMONE
MoranC1,SchoenmakersN1,MitchellC1,TalbotF1,WatsonL1,LyonsG1,Raymond‐BarkerP1,TaylorK2,HalsallD2,
ChatterjeeK1
1UniversityofCambridge,InstituteofMetabolicScience,Cambridge,UnitedKingdom,2Universityof
Cambridge,ClinicalBiochemistry,Cambridge,UnitedKingdom
FermiHall
08.00‐10.00OralSession4:ThyroidCellBiology(OP23‐OP30)
Chairpersons:SabineCostagliola,Belgium;MariastellaZannini,Italy
08.00‐08.15 OP23
PAX8EXPRESSIONISREQUIREDFORTHEDIFFERENTIATIONOFTHYROIDFOLLICULARCELLS
MarottaP1,AmendolaE1,DeLucaP1,ZoppoliP1,DiLauroR1,2,DeFeliceM1,2
1Biogem,ArianoIrpino(Av),Italy,2UniversityFedericoII,DBPCM,Napoli,Italy
10
08.15‐08.30 OP24
PAX8ISASURVIVALFACTORFORTHYROIDCELLSANDISINVOLVEDINTHECONTROLOFCELL
PROLIFERATION
DiPalmaT1,deCristofaroT1,FilipponeMG1,2,PierantoniGM2,FuscoA1,2,ZanniniM1
1InstituteofExperimentalEndocrinologyandOncology(IEOS)‐CNR,Naples,Italy,2UniversityofNaples
'FedericoII',Dpt.ofCellularandMolecularBiologyandPathology,Naples,Italy
08.30‐08.45 OP25
DYNAMICCHANGESOFLAMININEXPRESSIONANDBASEMENTMEMBRANEORGANIZATIONINTHE
DEVELOPINGTHYROID
JohanssonE1,JohanssonBR2,NilssonM1
1SahlgrenskaCancerCentre,SahlgrenskaAcademy,UniversityofGothenburg,Gothenburg,Sweden,2Electron
MicroscopyUnit,SahlgrenskaAcademy,UniversityofGothenburg,Gothenburg,Sweden
08.45‐09.00 OP26
GLOBALNOTCHPATHWAYPERTURBATIONSASANOVELMODELOFTHYROIDDYSGENESISIN
ZEBRAFISH
MarelliF1,PorazziP2,BenatoF3,ArgentonF3,TisoN3,PersaniL1,4
1IRCCSIstitutoAuxologicoItaliano,EndocrinologyandMetabolicDisorders,CusanoMilanino,Italy,2Childen's
HospitalofPhiladelphia,Philadelphia,UnitedStates,3UniversityofPadua,Padua,Italy,4UniversityofMilan,
Milan,Italy
09.00‐09.15 OP27
MOLECULARFUNCTIONSOFTHEDNAJC17PROTEIN,ACANDIDATEMODIFIERFORCONGENITAL
HYPOTHYROIDISM
FerrandinoG1,SpadaroO1,DiCampliA2,LuiniA2,deFranciscisV3,DeFeliceM1,4,DiLauroR1,4
1IRGS,Biogem,ArianoIrpino(AV),Italy,2IstitutodiBiochimicadelleproteinedelCNR,Napoli,Italy,3Istitutodi
EndocrinologiaedOncologiaSperimentaledelCNR,Napoli,Italy,4UniversitàdiNapoliFedericoII,
DipartimentodiBiologiaePatologiaCellulareeMolecolare,Napoli,Italy
09.15‐09.30 OP28
INVOLVEMENTOFNITRICOXIDEINIODINEDEFICIENCY‐INDUCEDANGIOGENESIS:ROLEOFNOS3AND
OFRYANODINERECEPTORS
CrapsJ1,VanderstraetenJ1,LobyshevaI2,BalligandJ‐L2,SonveauxP2,GilonP3,ColinIM1,GerardA‐C1
1UCL,PôledeMorphologie,Bruxelles,Belgium,2UCL,PôledePharmacologieExpérimentale,Bruxelles,Belgium,
3UCL,Pôled'endocrinologie,diabèteetnutrition,Bruxelles,Belgium
09.30‐09.45 OP29
CA2+‐BINDINGPROTEINEXPRESSIONINPRIMARYHUMANTHYROCYTES
LorenzS1,2,KrohnK1
11
1UniversityofLeipzig,MedicalFaculty,InterdisciplinaryCenterforClinicalResearch,Leipzig,Germany,
2UniversityofLeipzig,MedicalFaculty,DivisionofEndocrinologyandNephrology,Leipzig,Germany
09.45‐10.00 OP30
INTRATHYROIDREARRANGEMENTINSPACEENVIRONMENT
AlbiE1,CurcioF2,SpelatR2,LazzariniA2,LazzariniR1,CataldiS1,LoretiE3,FerriI3,Ambesi‐ImpiombatoFS2
1SphingolipidClub‐CRABioNResearchCentre,Perugia,Italy,2UniversityofUdine,DipartimentodiScienze
MedicheeBiologiche,Udine,Italy,3UniversityofPerugia,InstituteofPathologicAnatomyandHistology,
Perugia,Italy
10.00‐10.30 CoffeeBreak
FermiHall
10.30‐12.00Symposium3:Thyroidhormoneaction:theroleofTRαmutations
Chairpersons:GrahamWilliams,UK;PaoloBeck‐Peccoz,Italy
10.30.11.00 TRαmutantmousemodels:modelingahumandisorder
JensMittag,Sweden
11.00‐11.30 TRαmediatedresistancetothyroidhormone
KrishnaChatterjee,UK
11.30‐12.00 ClinicalphenotypeofTRαmutation
TheoVisser,TheNetherlands
MainAuditorium
10.30‐12.00 Symposium4:Anaplasticthyroidcarcinoma:frommolecularbiologyto
noveltherapeuticoptions
Chairpersons:JacquesDumont,Belgium;RossellaElisei,Italy
10.30.11.00 Molecularbiology CarineMaenhaut,Belgium 11.00‐11.30 Epidemiologicalanddiagnosticaspects
LaurenceLeenhardt,France
11.30‐12.00 Therapeuticoptions
BarbaraJarzab,Poland
PosterArea
12.00‐13.00 LunchandPosterDiscussion2(Poster122‐245)
PosterSession14:MTCClinical
Chairperson:JoaodeCastro,Portugal
PosterSession15:ThyroidCancerDiagnosticsBasic/Translational
Chairperson:GabriellaPellegritti,Italy
PosterSession16:ThyroidCancerDiagnosticsClinical2
Chairperson:JenniferSipos,USA
12
PosterSession17:ThyroidCancerTherapeuticsClinical2
Chairperson:IanHay,USA
PosterSession18:ThyroidAutoimmunityandHypothyroidism
Translational
Chairperson:MatthiasSchott,Germany
PosterSession19:ThyroidHormoneTransport
Chairperson:EdwardVisser,NL
PosterSession20:GoiterandNodularDiseaseClinical2
Chairperson:FrancoiseBorson‐Chazot,France
PosterSession21:CaseReports2
Chairperson:KostasMarkou,Greece
PosterSession22:ThyroidHormoneEffectsonMetabolismandBone
Chairperson:DuncanBassett,UK
PosterSession23:ThyroidHormoneAction2
Chairperson:FrancescoTrimarchi,Italy
PosterSession24:ThyroidFunctionRegulationBasic
Chairperson:DeniseCarvalho,Brazil
PosterSession25:ClinicalThyroidAutoimmunity2
Chairperson:ChantalDaumerie,Belgium
PosterSession26:EnvironmentalFactorsandDrugsaffectingThyroid
Function1
Chairperson:LeonidasDuntas,Greece
PosterSession27:Graves’OrbitopathyClinical2
Chairperson:JacquesOrgiazzi,France
MainAuditorium
13.00‐14.00AstraZenecaSymposium
HeraldingaNewEraintheTreatmentofAdvancedMedullary
ThyroidCancer
MainAuditorium
14.00‐14.45 ETAMerckSeronoPrizeLecture
Chairpersons:TheoVisser,TheNetherlands;LuigiBartalena,Italy
Thyroidhormoneactionsinboneandcartilage
GrahamWilliams,UK
14.45‐15‐00 CoffeeBreak
13
MainAuditorium
15.00‐16.30OralSession5:Autoimmunity(OP31‐OP36)
Chairpersons:SimonPearce,UK;MarcoCentanni,Italy
15.00‐15.15 OP31
CORTICOSTEROIDSANDRAPAMYCININHIBITTH1ANDTH2CHEMOKINESSECRETION,INDUCEDBY
CYTOKINES,INORBITALCELLSOFPATIENTSWITHGRAVES'OPHTHALMOPATHY
FerrariSM1,FallahiP1,RuffilliI1,DiDomenicantonioA1,SellariFranceschiniS2,FerranniniE1,AntonelliA1
1UniversityofPisa,SchoolofMedicine,DepartmentofInternalMedicine,Pisa,Italy,2UniversityofPisa,School
ofMedicine,OtorhinolaryngologyUnit,Pisa,Italy
15.15‐15.30 OP32
OXIDATIVESTRESSOFEYEMUSCULARCELLSINGRAVES'OPHTHALMOPATHYISASSOCIATEDTO
DOWN‐REGULATIONOFCAVEOLIN‐1ANDUPREGULATIONOFTYPEIII‐DEIODINASE
VanRegemorterE1,VanRegemorterV1,MariqueL1,SenouM1,deBournonvilleM1,DelacourtV1,BehetsC1,
LengeléB1,BrichardS2,BoschiA3,DaumerieC2,ManyM‐C1
1UCL,MORF,Bruxelles,Belgium,2UCL,Endocrinologie,Bruxelles,Belgium,3UCL,Ophthalmology,Bruxelles,
Belgium
15.30‐15.45 OP33
RELATIONSHIPBETWEENUSEOFIODIZEDSALTANDTHYROIDAUTOIMMUNITYAFTERUNIVERSAL
IODINEPROPHYLAXIS:THE2010PESCOPAGANOSURVEY
ProvenzaleMA1,FrigeriM1,PuleoL1,AntonangeliL1,RagoT1,FioreE1,TonaccheraM1,GrassoL1,PincheraA1,
Aghini‐LombardiF1,VittiP1
1UniversityofPisa,Endocrinology,Pisa,Italy
15.45‐16.00 OP34
CHARACTERIZATIONOFANOVELDETECTIONBIOASSAYFORTHYROIDBLOCKINGANTIBODY
LiY1,KimJ1,LarrimerA1,KlausenR1,YuL1,DianaT2,KahalyGJ2,OlivoPD1
1DiagnosticHybrids,Inc.(AQuidelCompany),R&D,Athens,UnitedStates,2GutenbergUniversityMedical
Center,ThyroidResearchLaboratory,Mainz,Germany
16.00‐16.15 OP35
TGABOFPATIENTSWITHSUBACUTETHYROIDITISARERESTRICTEDTOAMAJORBCELLEPITOPE
RicciD1,MontanelliL1,AlteaMA1,PucciA1,PincheraA1,VittiP1,LatrofaF1
1UniversityofPisa,DepartmentofEndocrinologyandMetabolism,Pisa,Italy
16.15‐16.30 OP36
RISKFACTORSFORPOST‐OPERATIVEDIPLOPIAINPRIMARYGAZEAFTERREHABILITATIVEORBITAL
DECOMPRESSIONFORGRAVES'ORBITOPATHY
14
LeoM1,LenziR2,MarinòM1,LatrofaF1,SistiE1,AlteaMA1,ProfiloMA1,MegnaL3,MazziB1,PincheraA1,VittiP1,
MarcocciC1,Sellari‐FranceschiniS2,RocchiR1
1UniversityofPisa,DepartmentofEndocrinologyandMetabolism,UnitofEndocrinology,Pisa,Italy,
2UniversityofPisa,DepartmentofNeuroscience,UnitofOtolaryngology,Pisa,Italy,3UniversityofPisa,
DepartmentofNeuroscience,UnitofOphthalmology,Pisa,Italy
FermiHall
15.00‐16.30OralSession6:Thyroidcellbiologyandcancer(OP37‐OP42)
Chairpersons:XavierdeDeken,Belgium;RosaMarinaMelillo,Italy
15.00‐15.15 OP37
THETHYROIDOXIDATIVECAPACITYISENHANCEDBYTHETH2CYTOKINES,IL‐4ANDIL‐13,THROUGH
INCREASEDEXPRESSIONOFTHEDUALOXIDASE2ANDITSMATURATIONFACTORDUOXA2
DeDekenX1,RaadH1,EskalliZ1,HosteC1,CorvilainB1,MiotF1
1UniversitéLibredeBruxelles,IRIBHM‐DUOXLab,Brussels,Belgium
15.15‐15.30 OP38
DNAMICROARRAYANDMIRNAANALYSESREINFORCETHECLASSIFICATIONOFFOLLICULARTHYROID
TUMOURS
JacquesC1,GuillotinD1,FrancB2,MalthieryY1,SavagnerF1
1InsermU694,Angers,France,2Laboratoired'Anatomopathologie,HopitalAPAré,BoulogneBillancourt,
France
15.30‐15.45 OP39
CAMPMAYNOTALWAYSBEAPROLIFERATIONSIGNALINTHYROIDCANCERCELLS
GrassiES1,DicitoreA2,BorghiMO3,4,VitaleG1,2,PersaniL1,2
1UniversitàdeglistudidiMilano,DipartimentodiScienzeMediche,Milan,Italy,2IstitutoAuxologicoItaliano,
LaboratoryofEndocrineandMetabolicResearch,Milan,Italy,3IstitutoAuxologicoItaliano,Laboratoryof
Immunology,Milan,Italy,4UniversitàdeglistudidiMilano,DipartimentodiMedicinaInterna,Milan,Italy
15.45‐16.00 OP40
GENOME‐WIDELINKAGEANALYSISTOIDENTIFYGENESINVOLVEDINTHYROIDGROWTHAND
NEOPLASIA
BakhshADQ1,2,HamshereM3,GregoryJ4,KirovG3,WilliamsD5,LudgateM1
1CardiffUniversity,InstituteofMolecular&ExperimentalMedicine,Cardiff,UnitedKingdom,2Instituteof
Molecular&ExperimentalMedicine,Endocrinology,Cardiff,UnitedKingdom,3CardiffUniversity,Psychological
Medicine&Neurology,Cardiff,UnitedKingdom,4InstituteofMolecular&ExperimentalMedicine,Department
ofChildHealth,Cardiff,UnitedKingdom,5CambridgeUniversity,StrangewaysLaboratory,Cambridge,United
Kingdom
16.00‐16.15 OP41
METABOLICENGINEERINGOFIODINECONTENTINARABIDOPSIS
15
LandiniM1,TonaccheraM2,GonzaliS1,AgrettiP3,DimidaA4,VittiP3,AlpiA5,PincheraA4,PerataP1
1ScuolaSAnnaPisa,PlantLab,Pisa,Italy,2UniversityofPisa,SchoolofMedicine,DepofEndocrinology,Pisa,
Italy,3UniversityofPisa,SchoolofMedicine,Pisa,Italy,4UniversityofPisa,Pisa,Italy,5UniversityofPisa,Dep
CropPlantBiology,Pisa,Italy
16.15‐16.30 OP42
RNA‐SEQPROVIDESISOFORMSPECIFICMIRNAEXPRESSIONDATAWHICHREQUIREISOFORMSPECIFIC
QPCRVERIFICATION
StokowyT1,2,SwierniakM1,WojtasB1,DanchM2,KrohnK3,FujarewiczK2,JarzabB1,PaschkeR4,EszlingerM4
1MariaSklodowska‐CurieMemorialCancerCenterandInstituteofOncology,NuclearMedicineandEndocrine
OncologyDepartment,Gliwice,Poland,2SilesianUniversityofTechnology,InstituteofAutomaticControl,
Gliwice,Poland,3UniversityofLeipzig,InterdisziplinaresZentrumfurKlinischeForschung,Leipzig,Germany,
4UniversityofLeipzig,KlinikfurEndokrinologieundNephrologie,Leipzig,Germany
16.45 DepartureforExcursion
16
TUESDAY,11thSeptember
MainAuditorium
08.00‐10.00OralSession7:PregnancyandIodine(OP43‐OP50)
Chairpersons:BijayVaidya,UK;FrancescoVermiglio,Italy
08.00‐08.15 OP43
THYROGLOBULINANTIBODIES:ANADDEDVALUEINTHEDETECTIONOFTHYROIDAUTOIMMUNITYIN
FEMALEPATIENTSOFINFERTILECOUPLES?
UnuaneD1,HaentjensP1,SchiettecatteJ1,TournayeH1,VelkeniersB1,PoppeK1
1UniversityHospitalUZ‐Brussel,FreeUniversityBrussels(VUB),Endocrinology,CentreforReproductive
MedicineandCentreforOutcomesResearchandLaboratoryforExperimentalSurgery,Brussels,Belgium
08.15‐08.30 OP44
THYROIDHORMONELEVELSINNORMALPREGNANCYAREASSOCIATEDWITHALTEREDMETABOLIC
PARAMETERS
KnightB1,2,ShieldsB1,HattersleyA1,2,Vaidya.B3,4
1PCMD(UniversityofExeter),PeninsulaNIHRClinicalResearchFacility,Exeter,UnitedKingdom,2RD&ENHS
FoundationTrust,Exeter,UnitedKingdom,3RD&ENHSFoundationTrust,DeptofDiabetesandEndocrinology,
Exeter,UnitedKingdom,4PCMD(UniversityofExeter),Exeter,UnitedKingdom
08.30‐08.45 OP45
THETYPE2DEIODINASETHR92ALAPOLYMORPHISMSEEMSTOBEAMARKEROFINCREASEDINSULIN
RESISTANCEDURINGPREGNANCY:AGENETICASSOCIATIONSTUDY
DoraJM1,WajnerS1,CostaJD1,PintoRibeiroRV1,LopesMG1,daSilvaAV1,LeiriaL1,CrispimD1,MaiaAL1
1HospitaldeClínicasdePortoAlegre,EndocrineDivision,PortoAlegre,Brazil
08.45‐09.00 OP46
IODINE‐CONTAININGMULTIVITAMINSFAILTOCORRECTIODINEDEFICIENCYINBELGIANPREGNANT
WOMEN
VandevijvereS1,AmsalkhirS2,MourriBensoudaA2,VanOyenH1,Moreno‐ReyesR2
1ScientificInstituteofPublicHealth,DepartmentofPublicHealthandSurveillance,Brussels,Belgium,2Hôpital
Erasme,UniversitéLibredeBruxelles,DepartmentofNuclearMedicine,Brussels,Belgium
09.00‐09.15 OP47
GLOBALIODINESTATUSIN2011ANDTRENDSOVERTHEPASTDECADE
AnderssonM1,KarumbunathanV1,ZimmermannMB1
1SwissFederalInstituteofTechnology(ETH)Zürich,DepartmentofHealthSciencesandTechnology(D‐HEST),
Zurich,Switzerland
17
09.15‐09.30 OP48
TIROKIDSTUDY:STATUSOFIODINENUTRITIONOFSPANISHINFANTS
VilaL1,DonnayS2,ArenaJ3,ArrizabalagaJJ4,PînedaJ5,GuzmánA6,LuengoLM7,VillarA8,BandrésO9,MuñozZ10,
GuerreroE11,MollG12,VichF12,MuñozJA13,RiestraM14,MenéndezE14,BeatoP7,AguirreM15,SantiagoP16,Aranda
J17,TorresY1,GentilA18,Serra‐PratM19,IodineDeficiencyandThyroidDisfunctiongroup(SEEN)
1HospitalMoisèsBroggi,EndocrinologyandNutrition,SantJoanDespí,Spain,2FundationHospitalAlcorcón,
EndocrinologyandNutrition,Alcorcón,Spain,3HospitalUniversitarioDonostia,Neonatology,SanSebastián,
Spain,4HospitalTxagorritxu,EndocrinologyandNutrition,Vitoria,Spain,5HospitalGarciaOrcoyen,
EndocrinologyandNutrition,Estella,Spain,6ComplejoAsistencialdeÁvila,EndocrinologyandNutrition,Ávila,
Spain,7HospitalUniversitarioInfantaCristina,EndocrinologyandNutrition,Badajoz,Spain,8HospitalClínico,
EndocrinologyandNutrition,Valladolid,Spain,9HospitalRoyoVillanova,EndocrinologyandNutrition,
Zaragoza,Spain,10CentrodeSaludArisa,Calatayud,Spain,11HospitalRíoCarrión,EndocrinologyandNutrition,
Palencia,Spain,12HospitaldeInca,EndocrinologyandNutrition,Inca,Spain,13ICS,ABS,Seud'Urgell,Spain,
14HospitalCentraldeAsturias,EndocrinologyandNutrition,Oviedo,Spain,15HospitalGeneral,Valladolid,
Spain,16ComplejoHospitalario,EndocrinologyandNutrition,Jaén,Spain,17HospitalVirgendelaLuz,Cuenca,
Spain,18HospitalUniversitarioVirgendelaMacarena,EndocrinologyandNutrition,Sevilla,Spain,19Hopitalde
Mataró,ResearchUnit,Barcelona,Spain
09.30‐09.45 OP49
BREADFORTIFICATIONWITHIODISEDSALTCORRECTSIODINEDEFICIENCYINSCHOOL‐AGED
CHILDRENBUTNOTINTHEIRMOTHERS:ANATIONALSURVEYINBELGIUM
Moreno‐ReyesR1,MourriBensoudaA1,AmsalkhirS1,AvniF2,VanOyenH3,VandevijvereS3
1HôpitalErasme,UniversitéLibredeBruxelles,DepartmentofNuclearMedicine,Brussels,Belgium,2Höpital
Erasme,UniversitéLibredeBruxelles,DepartmentofRadiology,Brussels,Belgium,3ScientificInstituteof
PublicHealth,DepartmentofPublicHealthandSurveillance,Brussels,Belgium
09.45‐10.00 OP50
PREDICTORSOFCHANGEINSERUMTSHAFTERIODINEFORTIFICATION:AN11YRFOLLOW‐UPOFTHE
DANTHYRSTUDY
BjergvedL1,2,JørgensenT2,3,PerrildH1,LaurbergP4,5,OvesenL6,RasmussenLB7,KnudsenN1
1BispebjergUniversityHospital,DepartmentofEndocrinologyandGastroenterology,Copenhagen,Denmark,
2ResearchCentreforPreventionandHealth,TheCapitalregionofDenmark,Glostrup,Denmark,3Facultyof
HealthandMedicalSciences,UniversityofCopenhagen,Copenhagen,Denmark,4AalborgHospital,Aarhus
UniversityHospital,DepartmentofEndocrinologyandMedicine,Aalborg,Denmark,5FacultyofMedicine,
AalborgUniversity,Aalborg,Denmark,6SlagelseHospital,DepartmentofGastroenterology,Slagelse,Denmark,
7NationalFoodInstitute,TechnicalUniversityofDenmark,DepartmentofNutrition,Søborg,Denmark
FermiHall
08.00‐10.00OralSession8:ThyroidCancerbasic(OP51‐OP58)
Chairpersons:DillwynWillliams,UK;MassimoSantoro,Italy
08.00‐08.15 OP51
IDENTIFICATIONOFNEWINHIBITORSOFRETRECEPTORTYROSINEKINASE
MocciaM1,GuidaT1,GrayN2,LiuQ2,CarlomagnoF1,SantoroM1
1UniversityofNaples,FedericoII,IstitutodiEndocrinologiaedOncologiaSperimentaledelCNR/Dipartimento
diBiologiaePatologiaCellulareeMolecolare“L.Califano”,FacoltàdiMedicinaeChirurgia,Naples,Italy,2Dana
18
FarberCancerInstitute,DepartmentofCancerBiology,HarvardMedicalSchool,DepartmentofBiological
ChemistryandMolecularPharmacology,BostonMassachusetts,UnitedStates
08.15‐08.30 OP52
3DCULTUREOFRECONSTITUTEDTHYROIDFOLLICLESFOREXVIVOEVALUATIONOFCANDIDATE
DRUGSINTERFERINGWITHCELLMIGRATION:APOTENTIALTUMORINVASIONASSAY
IngesonCarlssonC1,NilssonM1
1SahlgrenskaCancerCenter,SahlgrenskaAcademyattheUniversityofGothenburg,Gothenburg,Sweden
08.30‐08.45 OP53
CLM3,ANOVELMULTITARGETTYROSINEKINASEINHIBITORWITHANTIANGIOGENICPROPERTIES,IS
ACTIVEAGAINSTPRIMARYANAPLASTICTHYROIDCANCERINVITROANDINVIVO
FallahiP1,FerrariSM1,BocciG2,LaMottaC3,MancusiC1,CorradoA1,MaterazziG4,DanesiR2,DaSettimoF3,
MiccoliP4,AntonelliA1
1UniversityofPisa,SchoolofMedicine,DepartmentofInternalMedicine,Pisa,Italy,2UniversityofPisa,School
ofMedicine,DivisionofPharmacology,Pisa,Italy,3UniversityofPisa,SchoolofMedicine,Departmentof
PharmaceuticalScience,Pisa,Italy,4UniversityofPisa,DepartmentofSurgery,Pisa,Italy
08.45‐09.00 OP54
MICRORNASINFLUENCETHETUMORIGENESISOFCOLDBENIGNTHYROIDNODULESBYACTINGON
CELLCYCLEANDAPOPTOSIS
FerrazC1,LorenzS1,MollA1,PaschkeR1,EszlingerM1
1UniversitätLeipzig,EndocrinologyandNephrology,Leipzig,Germany
09.00‐09.15 OP55
TRAILCANEFFICIENTLYKILLANAPLASTICTHYROIDCANCER(ATC)CELLSINVITROANDINVIVO
PilliT1,2,RanganathR2,CarrR2,QinJ2,MakerAV2,3,LiLC2,PaciniF1,PrabhakarBS2
1UniversityofSiena,DepartmentofInternalMedicine,Endocrinology&MetabolismandBiochemistry,Siena,
Italy,2UniversityofIllinoisatChicago,DepartmentofMicrobiology&Immunology,Chicago,UnitedStates,
3UniversityofIllinoisatChicago,DepartmentofSurgery,Chicago,UnitedStates
09.15‐09.30 OP56
THERAPEUTICSTRATEGYTOTARGETTHERECEPTORTYROSINEKINASEAXLINTHYROIDCANCER
KrishnamoorthyGP1,GuidaT1,ViscianoC1,LiottiF1,CarlomagnoF1,MelilloRM1
1UniversityofNaples‐FedericoII,DipartimentodiBiologiaePatologiaCellulareeMolecolare/Istitutodi
EndocrinologiaedOncologiaSperimentaledelCNR”G.Salvatore”,Napoli,Italy
09.30‐09.45 OP57
HYPERMETHYLATIONOFANEWCPGISLANDISASSOCIATEDWITHREDUCEDNISGENEEXPRESSIONIN
19
THYROIDTUMORS
GalraoAL1,SodréAK1,CamargoRY1,FrigugliettiCU1,KulcsarMA1,LimaEU1,MoraesLS2,CeruttiJM2,Medeiros‐
NetoG1,RubioIG3
1UniversityofSaoPauloMedicalSchool,Endocrinology‐Thyroid,SaoPaulo,Brazil,2UNIFESPEPM,Genetics,
SaoPaulo,Brazil,3UNIFESP,BiologicalSciences,SãoPaulo,Brazil
09.45‐10.00 OP58
IDENTIFICATIONOFTARGETSOFTWIST1TRANSCRIPTIONFACTORINANAPLASTICTHYROIDCANCER
DiMaroG1,OrlandellaFM1,SalernoP1,BencivengaTC1,SantoroM1,SalvatoreG2
1UniversityofNaples,FedericoII,Naples,Italy,2UniversityofNaplesParthenope,Naples,Italy
10.00‐10.30 CoffeeBreak
FermiHall
10.30‐12.00 Symposium5:Signalinginthethyroid
Chairpersons:PilarSantisteban,Spain;AlfredoFusco,Italy
10.30‐11.00 Requirementsfornormalthyroiddifferentiation SabineCostagliola,Belgium 11.00‐11.30 PI3K/PTENsignalinginthethyroid
AntonioDeCristofano,USA 11.30‐12.00 Rasandtransformationofthyroidcells
GabrielladeVita,Italy
MainAuditorium
10.30‐12.00 Symposium6:TSHreceptorinthyroidautoimmunity
Chairpersons:GeorgeJ.Kahaly,Germany;LucaChiovato,Italy
10.30‐11.00 InteractionoftheTSHreceptorwithautoantibodies:structureanddynamics JaneSanders,UK
11.00‐11.30 BioassaysforTSHreceptorautoantibodies
GiorgioNapolitano,Italy 11.30‐12.00 Thyroidblockingantibodies:methodologyandclinicalrelevance
PaulOlivo,USA
PosterArea
12.00‐13.00 LunchandPosterDiscussion3(Poster246‐331)
PosterSession28:Thyroidcancerdiagnosticsclinical3
Chairperson:PhilippeCaron,France
PosterSession29:thyroidcancertherapeuticsclinical3
Chairperson:SophieLeboulleux,France
PosterSession30:Thyroidcancerpathogenesistranslational/clinical.
Chairperson:ClaraAlvarez,Spain
PosterSession31:Thyroidhormoneandreproduction/fetal‐maternal
unit
Chairperson:KrisPoppe,Belgium
20
PosterSession32:Environmentalfactorsanddrugsaffectingthyroid
function2
Chairperson:PeterSmyth,Ireland
PosterSession33:Hypothyroidismclinical2
Chairperson:SalvatoreBenvenga,Italy
PosterSession34:Hyperthyroidismclinical
Chairperson:FaustoBogazzi,Italy
PosterSession35:Graves’diseaseandorbitopathybasic/translational
Chairperson:MilosZarkovic,Serbia
PosterSession36:Thyroidglanddevelopment/thyroidhormone
synthesis
Chairperson:MikaelNilsson,Sweden
PosterSession37:Clinicalthyroidology
Chairperson:RoussankaKovatcheva,Bulgaria
MainAuditorium
13.00‐14.00IBSASymposium
13.00
13.05 13.25 13.30 13.50 13.55 14.00 Controversiesonlevothyroxinetherapy
Chairmen:AldoPinchera(Pisa,Italy)andP.ReedLarsen(Boston,USA)
Introduction
P.ReedLarsen(Boston,USA)
Levothyroxinetherapyinnodulargoiter
LaszloHegedüs(Odense,Denmark)
PaoloVitti(Pisa,Italy)
Q&ASession
Moderation:P.ReedLarsen(Boston,USA)
Replacementtherapyinhypothyroidism
BernadetteBiondi(Naples,Italy)
P.ReedLarsen(Boston,USA)
Q&ASession
Moderation:AldoPinchera(Pisa,Italy)
Conclusions
AldoPinchera
EndofSession
14.00‐14.45Meet‐the‐Expert9‐11
MainAuditorium
14.00‐14.45 MTE9:GenomeWideAssociationAnalysisandthyroidfunction,recent
outcomesandfuturechallenges
RobinPeeters,TheNetherlands
21
FermiHall
14.00‐14.45 MTE10:Stressandthyroidautoimmunity
AgathoclesTsatsoulis,Greece
PacinottiHall
14.00‐14.45 MTE11:Low‐riskthyroidcarcinoma
MariaAlevizaki,Greece
MainAuditorium
15.00‐17.00OralSession9:Thyroidnodulesandcancer(OP59‐OP66)
Chairpersons:SteenBonnema,Denmark;LauraFugazzola,Italy
15.00‐15.15 OP59
TI‐RADSSCORE:DIAGNOSTICPERFORMANCEWITHANDWITHOUTELASTOGRAPHYPROSPECTIVE
STUDYON1305THYROIDNODULES
RussG1,2,RouxelA1,2,Bienvenu‐PerrardM1,3,RoyerB1,4,BigorgneC1,LeenhardtL2
1CentredePathologieetd'Imagerie,Paris,France,2HopitalLaPitiéSalpétrière,ServicedeMédecineNucléaire
duPrAurengo,Paris,France,3HôpitalCochin,ServicedeMédecineNucléaireduPrRichard,Paris,France,
4HopitalCochin,Serviced'AnatomopathologieduPrVacher‐Lavenu,Paris,France
15.15‐15.30 OP60
INTERSTITIALLASERPHOTOCOAGULATION(ILP)OFBENIGNCYSTICTHYROIDNODULES‐A
PROSPECTIVERANDOMIZEDCONTROLLEDTRIAL
DøssingH1,BennedbækFN2,HegedüsL3
1OdenseUniversityHospital,Oto‐Rhino‐LaryngologyandNeckSurgery,Odense,Denmark,2HerlevHospital,
Endocrinology,Herlev,Denmark,3OdenseUniversityHospital,Endocrinology,Odense,Denmark
15.30‐15.45 OP61
MULTICENTERRANDOMIZEDPROSPECTIVETRIALOFPERCUTANEOUSLASERABLATIONVERSUS
FOLLOW‐UPFORTHETREATMENTOFCOLDTHYROIDNODULES‐TWELVE‐MONTHRESULTS
RagoT1,PapiniE2,VittiP1,DeFeoP3,GambelungheG3,ValcaviR4,BizzarriG5,PacellaCM6
1UniversityofPisa,EndocrinologyDept,Pisa,Italy,2ReginaApostolorumHospital,EndocrinologyDept,Albano
Laziale,Italy,3UniversityofPerugia,DepartmentofInternalMedicineandEndocrineandMetabolicSciences,
Perugia,Italy,4ArcispedaleSantaMariaNuova,EndocrineUnit&ThyroidDiseasesCenter,ReggioEmilia,Italy,
5ReginaApostolorumHospital,RadiologyDept,AlbanoLaziale,Italy,6ReginaApostolorumHospital,
InterventionalRadiology,AlbanoLaziale,Italy
15.45‐16.00 OP62
ULTRASOUND‐GUIDEDPERCUTANEOUSETHANOLABLATION(UPEA)OFSELECTEDNECKNODAL
METASTASES(NNM)INDIFFERENTIATEDTHYROIDCARCINOMA(DTC):A21‐YEAREXPERIENCEIN161
PATIENTS
HayI1,LeeR1,Davidge‐PittsC1,GeskeJ1,ReadingC1,CharboneauW1
1MayoClinic,Rochester,UnitedStates
22
16.00‐16.15 OP63
LEPTINANDSERUMTHYROTROPINCONCENTRATIONSINAREPRESENTATIVESAMPLEOFIODINE‐
SUFFICIENT,EUTHYROIDMEDITERRANEANPOPULATIONWITHDIFFERENTBODYMASSINDEX.
RELATIONSHIPWITHTHYROIDAUTOIMMUNITYANDSMOKINGHABIT
LucasA1,GranadaML2,OlaizolaI1,CastellC3,JulianMT1,PelliteroS1,Puig‐DomingoM1
1GermansTriasiPujol,Hospital,EndocrinologiaiNutrició,Badalona,Spain,2GermansTriasiPujol,Hospital,
HormoneLaboratory,Badalona,Spain,3GeneralDirectionofPublicHealth,HealthDepartment,Generalitatof
Catalonia,Barcelona,Spain
16.15‐16.30 OP64
STAGEIPAPILLARYTHYROIDCARCINOMASWITHHIGHPERCENTAGEOFBRAFV600EALLELESHAVEA
HIGHRISKOFRECURRENCE
GuerraA1,FugazzolaL2,RossiS2,CirielloV2,FornoI2,MarottaV3,CirilloM1,DiStasiV1,VolpeA1,MurinoA1,Izzo
G1,VitaleM1
1UniversityofSalerno,DepartmentofMedicineandSurgery,Baronissi,Italy,2UniversityofMilan,Milan,Italy,
3UniversityofNaples“FedericoII',Naples,Italy
16.30‐16.45 OP65
QUALITYOFLIFEANDDEPRESSIONINPATIENTSWITHDIFFERENTIATEDTHYROIDCARCINOMA
MolinaroE1,LippiC1,PiaggiP2,AgateL1,PassannantiP1,ValeriaB1,BiaginiA1,SantiniF1,VittiP1,PincheraA1,
EliseiR1
1DepartmentofEndocrinology,UniversityofPisa,Pisa,Italy,2DepartmentofEnergyandSystemsEngineering,
UniversityofPisa,Pisa,Italy
16.45‐17.00 OP66
OBESITYANDOVERWEIGHTAREMAJORRISKFACTORSOFRECURRENCEAFTERTHYROIDECTOMYFOR
MACROSCOPICPAPILLARYCANCER
TresalletC1,NoulletS1,Godiris‐PetitG1,HoangC2,LeenhardtL3,MenegauxF1
1APHP,UniversitéPierreetMarieCurie,Paris6,EndocrineSurgery,Paris,France,2APHP,UniversitéPierreet
MarieCurie,Paris6,PathologyDepartement,Paris,France,3APHP,UniversitéPierreetMarieCurie,Paris6,
NuclearMedicine,Paris,France
FermiHall
15.00‐17.00 OralSession10:ThyroidBasic1(OP67‐OP74)
Chairpersons:UlrichSchweizerGermany;MonicaDentice,Italy
15.00‐15.15 OP67
THETHYROIDHORMONERECEPTOR‐COACTIVATORINTERFACEMEDIATESNEGATIVEFEEDBACK
REGULATIONOFTHEHUMANPITUITARYTHYROIDAXIS
AgostiniM1,MoranC1,SchoenmakersE1,MitchellC1,GregoryJ2,GurnellM1,ChatterjeeK1
1UniversityofCambridge,InstituteofMetabolicScience,Cambridge,UnitedKingdom,2UniversityHospital
Wales,DepartmentofChildHealth,Cardiff,UnitedKingdom
23
15.15‐15.30 OP68
ROLEOFCYSTEINERESIDUESINTHEMCT8THYROIDHORMONETRANSPORTER
LimadeSouzaEC1,GroenewegS1,VisserEW1,PeetersRP1,VisserTJ1
1EramusUniversityMedicalCenter,InternalMedicine,Rotterdam,TheNetherlands
15.30‐15.45 OP69
UNCOUPLINGPROTEIN‐3(UCP3)ISINVOLVEDINMETABOLICADAPTATIONINDUCEDBY
TRIIODOTHYRONINE.
LombardiA1,BusielloRA1,SeneseR2,CioffiF3,GogliaF3
1UniversityofNaples'FedericoII',BiologicalScience,Napoli,Italy,2SecondUnivesityofNaples(SUN),Caserta,
Italy,3SannioUniversity,Benevento,Italy
15.45‐16.00 OP70
ABSENCEOFTYPE3DEIODINASELEADSTORESTRICTIVECARDIOMYOPATHYANDAGGRAVATES
CARDIACHYPERTROPHYINMICE
OlivaresEL1,UetaCB2,OskoueiBN3,PintoJR4,CorreaMM2,SimovicG2,SimonidesWS5,HareJM3,BiancoAC2
1FederalRuralUniversityofRiodeJaneiro,PhysiologicalSciences,Seropedica,Brazil,2UniversityofMiami
MillerSchoolofMedicine,DivisionofEndocrinology,DiabetesandMetabolism,Miami,UnitedStates,
3UniversityofMiamiMillerSchoolofMedicine,InterdisciplinaryStemCellInstitute,Miami,UnitedStates,
4UniversityofMiamiMillerSchoolofMedicine,DepartmentofMolecularandCellularPharmacology,Miami,
UnitedStates,5UniversityMedicalCenter,InstituteforCardiovascularResearch,Amsterdam,TheNetherlands
16.00‐16.15 OP71
THEINTRACELLULARINACTIVATIONOFTHYROIDHORMONESIGNALINGINMUSCLESTEMCELLSIS
REQUIREDFORSUCCESSFULMUSCLEREGENERATION
DenticeM1,AmbrosioR1,SibilioA1,LuongoC1,DamianoV1,BonelliC1,DeStefanoA1,FenziG1,LarsenPR2,
SalvatoreD1
1UniversityofNaples“FedericoII',DepartmentofMolecularandClinicalEndocrinologyandOncology,Naples,
Italy,2BrighamandWomen'sHospitalandHarvardMedicalSchool,ThyroidSection,DivisionofEndocrinology,
DiabetesandHypertension,Boston,UnitedStates
16.15‐16.30 OP72
FUNCTIONALANALYSISOFNEWLYDISCOVEREDMUTATIONSINTHESECISELEMENTOFTHETHYROID
HORMONEACTIVATINGTYPE2DEIODINASE
ZevenbergenC1,VisserWE1,VisserTJ1
1ErasmusMedicalCenter,InternalMedicine,Rotterdam,TheNetherlands
16.30‐16.45 OP73
ALTERNATIVESPLICINGOFTYPE1IODOTHYRONINEDEIODINASEINPITUITARYADENOMAIS
REGULATEDBYPROTO‐ONCOGENICSPLICINGFACTORSF2/ASF
KedzierskaH1,PoplawskiP1,MaksymowiczM2,GrajkowskaW3,4,MatyjaE3,5,BonickiW5,NaumanP6,Piekielko‐
WitkowskaA1
1TheMedicalCentreofPostgraduateEducation,DepartmentofBiochemistry,Warsaw,Poland,2M.Sklodowska‐
CurieMemorialCancerCentreandInstituteofOncology,DepartmentofPathology,Warsaw,Poland,3M.
MossakowskiMedicalResearchCentre,PolishAcademyofSciences,DepartmentofExperimentalandClinical
Neuropathology,Warsaw,Poland,4TheChildren'sMemorialHealthInstitute,DepartmentofPathology,
24
Warsaw,Poland,5M.Sklodowska‐CurieMemorialCancerCentreandInstituteofOncology,Departmentof
Neurosurgery,Warsaw,Poland,6InstitutofPsychiatryandNeurology,DepartmentofNeurosurgery,Warsaw,
Poland
16.45‐17.00 OP74
ACONTRIBUTINGROLEFORHEPATICSIRTUINSINTHEPREVENTIONOFDIET‐INDUCEDADIPOSITYBY
3,5‐DIIODO‐L‐THYRONINE(T2)
deLangeP1,SeneseR1,CioffiF2,deMatteisR3,ZielloA1,GogliaF2,LanniA1
1SecondUnivesityofNaples(SUN),Caserta,Italy,2UniversityofSannio,Benevento,Italy,3UniversitàdegliStudi
diUrbino'CarloBo',Urbino,Italy
MainAuditorium
17.15‐18.45 ETAGeneralAssembly
20.00 GalaDinner
25
WEDNESDAY,12thSeptember
MainAuditorium
07.45‐08.45 Shortcall/latebreakingpresentations(15minx4)
08.45‐09.00 CoffeeBreak
MainAuditorium
09.00‐11.00OralSession11:ThyroidCancer(OP75‐OP82)
Chairpersons:JanSmit,TheNetherlands;FrancescaCarlomagno,Italy
09.00‐09.15 OP75
THEPREVALENCEOFRASMUTATIONSINANITALIANMEDULLARYTHYROIDCANCERSERIESANDA
META‐ANALYSISOFPUBLISHEDSTUDIES
CiampiR1,MianC2,FugazzolaL3,CosciB1,RomeiC1,BarolloS2,CirelloV3,BotticiV1,MarconciniG1,PelizzoMR4,
BorrelloMG5,BasoloF6,UgoliniC6,MaterazziG6,PincheraA1,EliseiR1
1UniversitàdiPisa,DepartmentofEndocrinologyandMetabolism,Pisa,Italy,2UniversitàdiPadova,
DepartmentofMedicine‐DIMED,Padova,Italy,3FondazioneIRCCSCa'Granda,EndocrineUnit,Milano,Italy,
4UniversitàdiPadova,DepartmentofSurgical,OncologicalandGastroenterologicalSciences‐DISCOG,Padova,
Italy,5FondazioneIRCCSIstitutoNazionaledeiTumori,ExperimentalOncologyDepartment‐U.O.Molecular
Mechanisms,Milano,Italy,6UniversitàdiPisa,DepartmentofSurgery,Pisa,Italy
09.15‐09.30 OP76
CLINICOPATHOLOGICCHARACTERISTICSOFPAPILLARYTHYROIDCARCINOMABASEDONAGEGROUPS
ParkYS1,JungSP1,LeeJ1,KimJ1,ChoiMY1,LeeSK1,KilWH1,LeeJE1,NamSJ1,ChoeJH1,KimJH1,KimJS1
1SungkyunkwanUniv.,SchoolofMedicine,DepartmentofSurgery,Seoul,Korea,Republicof
09.30‐09.45 OP77
PAPILLARYTHYROIDCANCERGENEPROFILEMODIFICATIONOVERTHELAST15YEARS
RomeiC1,FugazzolaL2,PuxedduE3,FrascaF4,ViolaD1,MuzzaM2,MorettiS3,NicolosiML4,GianiC1,CirelloV2,
AveniaN5,RossiS6,VittiP1,PincheraA1,EliseiR1
1UniversityofPisa,DepartmentofEndocrinology,Pisa,Italy,2UniversityofMilano,DepartmentofMedical
Sciences,Milano,Italy,3UniversityofPerugia,DepartmentofMedicine,Perugia,Italy,4UniversityofCatania,
DepartmentofClinicalandMoleculaBiomedicine,Catania,Italy,5UniversityofPerugia,DepartmentofSurgical,
RadiologicalandOdontostomatologicSciences,Perugia,Italy,6AOSanPaolo,DepartmentofAnatomic
Pathology,Milano,Italy
09.45‐10.00 OP78
THEMAJORIMPORTANCEOFAGEATEXPOSUREANDLATENCYONTHENUMBERANDPROPORTIONOF
THYROIDCARCINOMASINBELARUSDUETOCHERNOBYL,A25YEARSTUDY
DemidchikY1,WilliamsD2
1BelarussianStateMedicalUniversity,Minsk,Belarus,2CambridgeUniversity,Cambridge,UnitedKingdom
26
10.00‐10.15 OP79
ISTHEGENETICPREDISPOSITIONTOPAPILLARYMICROCANCERTHESAMEASFORCLINICALLY
EVIDENTPTC?
KalembaM1,Handkiewicz‐JunakD1,KulaD1,Oczko‐WojciechowskaM1,KowalM1,TyszkiewiczT1,Zebracka‐Gala
J1,PolańskaJ2,JarzabB1
1MariaSklodowska‐CurieMemorialCancerCenterandInstituteofOncology,Dept.ofNuclearMedicineand
EndocrineOncology,Gliwice,Poland,2SilesianUniversityofTechnology,InstituteofAutomaticControl,
Gliwice,Poland
10.15‐10.30 OP80
LONGTERMEFFICACYANDTOLERABILITYOFSORAFENIBINDIFFERENTIATEDTHYROIDCARCINOMA:
FINALRESULTSOFAPHASEIITRIAL
SchneiderT1,AbdulrahmanR1,KapiteijnE1,SmitJW1
1LeidenUniversityMedicalCenter,Leiden,TheNetherlands
10.30‐10.45 OP81
DIAGNOSTICIMPACTOFTHEDETECTIONOFPOINTMUTATIONSANDREARRANGEMENTSIN320
ROUTINEAIRDRIEDFINENEEDLEASPIRATION(FNA)SMEARS
EszlingerM1,MuenzS1,FerrazC1,RehfeldC1,KrogdahlA2,JensenE2,BoesenbergE1,HegedusL3,PaschkeR1
1UniversityofLeipzig,DivisionsofEndocrinologyandNephrology,Leipzig,Germany,2OdenseUniversity
Hospital,DepartmentofPathology,Odense,Denmark,3OdenseUniversityHospital,Departmentof
EndocrinologyandMetabolism,Odense,Denmark
10.45‐11.00 OP82
EXPRESSIONPATTERNSINPAPILLARYTHYROIDCARCINOMASWITHBRAFV600EORRET/PTC
SUGGESTSACTIVATIONOFDIFFERENTPATHWAYS
BastosAU1,OlerG1,CeruttiJM1
1GeneticBasesofThyroidTumorsLaboratory,UniversidadeFederaldeSãoPaulo,DepartmentofMorphology
andGenetics,SãoPaulo,Brazil
FermiHall
09.00‐11.00OralSession12:ThyroidBasic2(OP83‐OP90)
Chairpersons:LutzSchomburg,Germany;LucaPersani,Italy
09.00‐09.15 OP83
DOSEDEPENDENTEFFECTSOFABLOCKINGTYPEMONOCLONALAUTOANTIBODY(K1‐70)IN
HYPERTHYROIDRATS
FurmaniakJ1,SandersJ1,YoungS1,KabelisK1,SandersP1,EvansM1,ClarkJ1,WilmotJ1,ReesSmithB1
1FIRSLaboratories,RSRLtd,Cardiff,UnitedKingdom
09.15‐09.30 OP84
MOLECULARSAMPLINGOFTSHRECEPTORALLOSTERICBINDINGPOCKET:SWITCHINGAGONISMTO
ANTAGONISMANDREVERSE
HoyerI1,HaasA‐K1,FurkertJ1,RutzC1,SchüleinR1,KrauseG1
1Leibniz‐InstitutfürMolekularePharmakologie(FMP),Berlin,Germany
27
09.30‐09.45 OP85
THYROTROPINRECEPTOR(TSHR)ACTIVATIONENHANCESSUBCUTANEOUSADIPOGENESIS,
FAVOURINGBROWNADIPOSETISSUE(BAT)FORMATION,AROLEFORHYALURONAN?
ZhangL1,Grennan‐JonesF1,DayanCM1,ReesDA1,LudgateM1
1CardiffUniversity,SchoolofMedicine,Cardiff,UnitedKingdom
09.45‐10.00 OP86
EFFECTSOFINVIVO3‐IODOTHYRONAMINEADMINISTRATIONONGENEEXPRESSIONINADIPOSE
TISSUE,LIVERANDHEART
RighiM1,IofridaC1,MelissariE1,MariottiV1,DiRussoM1,PellegriniS1,ZucchiR1
1UniversitàdiPisa,Pisa,Italy
10.00‐10.15 OP87
METABOLOMEDYNAMICSOFT1AM,ANENDOGENOUSTHYROIDHORMONEDERIVATIVE:EFFECTSON
LIPIDMETABOLISM,WEIGHTLOSS,ANDAPPETITEINMICE
Assadi‐PorterF1,ReilandH1,ButzD1,TonelliM1,GhelardoniS2,ScanlanT3,ZucchiR2,ChielliniG2
1UWMadison,Biochemistry,Madison,UnitedStates,2UniversityofPisa,Scienzedell'Uomoedell'Ambiente,
Pisa,Italy,3OHSUPortland,Oregon,Portland,UnitedStates
10.15‐10.30 OP88
3,5‐DIIODOTHYRONINEADMINISTRATIONIMPROVESCHOLESTEROLMETABOLISMINLDLRECEPTOR
KNOCK‐OUTMICE(LDLR‐/‐)BYMODIFYINGHEPATICPROTEOMICPROFILE
MorenoM1,SilvestriE1,GlinniD1,GoldbergIJ2,EhrenkranzJ3,ScanlanTS4,GogliaF1
1UniversityofSannio,Benevento,Italy,2ColumbiaU.CollegeofPhysiciansandSurgeons,NewYork,United
States,3IntermountainHealthcare,Murray,UnitedStates,4OregonHealthSciencesUniversity,Portland,United
States
10.30‐10.45 OP89
THEROLEOFCONSERVEDCHARGEDAMINOACIDSINTRANSMEMBRANEDOMAINSOFTHETHYROID
HORMONETRANSPORTERMCT8
GroenewegS1,FriesemaECH1,VisserTJ1
1ErasmusMC,InternalMedicine,Rotterdam,TheNetherlands
10.45‐11.00 OP90
MUTATIONSOFMCT8INPATIENTSWITHALLAN‐HERNDON‐DUDLEYSYNDROMEAFFECTITS
CELLULARDISTRIBUTION
KersseboomS1,FriesemaECH1,VisserWE1,KlootwijkW1,VisserTJ1
1EramusUniversityMedicalCenter,InternalMedicine,Rotterdam,TheNetherlands
11.00‐11.15 CoffeeBreak
FermiHall
11.15‐12.45Symposium7:Theimportanceoftransportanddeiodinationinbrain
Chairpersons:JosefKöhrle,Germany;DomenicoSalvatore,Italy
11.15‐11.45 “Secondary”thyroidhormonetransporters
28
UlrichSchweizer,Germany 11.45‐12.15 Theroleofdeiodinasesinthecontrolofbraingeneexpression JuanBernal,Spain 12.15‐12.45 TheT4transporterOatp1c1
HeikeHeuer,Germany
MainAuditorium
11.15‐12.45 Symposium8:Thyroidnodules:updateinthemanagement
Chairpersons:RalfPaschke,Germany;FurioPacini,Italy
11.15‐11.45 Molecularevaluationofindeterminatenodules:isthereanyaddedvalue?
FrédériqueSavagner,France
11.45‐12.15 TSHlevelsandriskofcancer
PaoloVitti,Italy
12.15‐12.45 Non‐surgicallocalintervention
EnricoPapini,Italy
MainAuditorium
12.45‐13.15 YoungInvestigatorAwards,PosterPrizes,JackRobbinsPrizeand
ClosingCeremony
29